Cutia Therapeutics

SEHK:2487 Stock Report

Market Cap: HK$2.6b

Cutia Therapeutics Management

Management criteria checks 3/4

Cutia Therapeutics' CEO is Lele Zhang, appointed in Sep 2019, has a tenure of 5.67 years. total yearly compensation is CN¥27.08M, comprised of 10.7% salary and 89.3% bonuses, including company stock and options. directly owns 4.65% of the company’s shares, worth HK$123.00M. The average tenure of the management team and the board of directors is 3 years and 4.8 years respectively.

Key information

Lele Zhang

Chief executive officer

CN¥27.1m

Total compensation

CEO salary percentage10.66%
CEO tenure5.7yrs
CEO ownership4.7%
Management average tenure3yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

Is Cutia Therapeutics (HKG:2487) A Risky Investment?

May 08
Is Cutia Therapeutics (HKG:2487) A Risky Investment?

Not Many Are Piling Into Cutia Therapeutics (HKG:2487) Stock Yet As It Plummets 37%

Apr 08
Not Many Are Piling Into Cutia Therapeutics (HKG:2487) Stock Yet As It Plummets 37%

Does Cutia Therapeutics (HKG:2487) Have A Healthy Balance Sheet?

Aug 30
Does Cutia Therapeutics (HKG:2487) Have A Healthy Balance Sheet?

A Look At The Intrinsic Value Of Cutia Therapeutics (HKG:2487)

Jun 03
A Look At The Intrinsic Value Of Cutia Therapeutics (HKG:2487)

Analysts Are Betting On Cutia Therapeutics (HKG:2487) With A Big Upgrade This Week

Apr 08
Analysts Are Betting On Cutia Therapeutics (HKG:2487) With A Big Upgrade This Week

CEO Compensation Analysis

How has Lele Zhang's remuneration changed compared to Cutia Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024CN¥27mCN¥3m

-CN¥434m

Sep 30 2024n/an/a

-CN¥479m

Jun 30 2024n/an/a

-CN¥524m

Mar 31 2024n/an/a

-CN¥1b

Dec 31 2023CN¥51mCN¥3m

-CN¥2b

Sep 30 2023n/an/a

-CN¥2b

Jun 30 2023n/an/a

-CN¥2b

Mar 31 2023n/an/a

-CN¥1b

Dec 31 2022CN¥21mCN¥4m

-CN¥556m

Dec 31 2021CN¥27mCN¥3m

-CN¥320m

Compensation vs Market: Lele's total compensation ($USD3.76M) is above average for companies of similar size in the Hong Kong market ($USD441.34K).

Compensation vs Earnings: Lele's compensation has been consistent with company performance over the past year.

CEO

Lele Zhang (46 yo)

5.7yrs
Tenure
CN¥27,084,000
Compensation

Ms. Lele Zhang is founder of Cutia Therapeutics. She serves as Director of Cutia Therapeutics since May 12, 2020 and serves as Executive Director since November 15, 2022. Ms. Zhang has been Chief Executive...

Leadership Team

NamePositionTenureCompensationOwnership
Lele Zhang
Founder5.7yrsCN¥27.08m4.65%
HK$ 123.0m
Yuqing Huang
CFO & Executive Director4yrsCN¥9.54m0.027%
HK$ 705.5k
Qi Zhu
Chief Medical Officer5.7yrsno datano data
Lei Lei
Senior Vice President of Research & Development Department2.7yrsno datano data
Chunna Zhang
Senior Vice President of Regulatory Affairs Department2.7yrsno datano data
Jingxin Xu
Senior Vice President of Manufacturing & Quality Control Department3.3yrsno datano data
Jiaru Wu
Senior Vice President of Finance & Integrated Management Department2.5yrsno datano data
Sze Ting Chan
Company Secretary2.5yrsno datano data
3.0yrs
Average Tenure
43yo
Average Age

Experienced Management: 2487's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Lele Zhang
Founder5yrsCN¥27.08m4.65%
HK$ 123.0m
Yuqing Huang
CFO & Executive Director2.5yrsCN¥9.54m0.027%
HK$ 705.5k
Lian Yong Chen
Non-Executive Chairman of the Board5.8yrsno datano data
Ming Kit Chung
Independent Non-Executive Director2yrsCN¥350.00kno data
Yunxia Yang
Non-Executive Director4.8yrsno datano data
Qin Xie
Non-Executive Director5.8yrsno datano data
Xiao Huang
Non-Executive Director4.8yrsno datano data
Tak Yan Tao
Independent Non-Executive Director2yrsCN¥350.00kno data
Xiaoxiang Ye
Independent Non-Executive Director2yrsCN¥350.00kno data
4.8yrs
Average Tenure
46yo
Average Age

Experienced Board: 2487's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/22 02:57
End of Day Share Price 2025/05/22 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cutia Therapeutics is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhuonan XuChina International Capital Corporation Limited
Hangci ZhengChina International Capital Corporation Limited
Yifan DuCitic Securities Co., Ltd.